Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Latest Opioid Dilemma: Can Apadaz Stop Snorting Abuse – And Does That Even Matter?

This article was originally published in The Pink Sheet Daily

Executive Summary

KemPharm's immediate-release hydrocodone combination product has limited data about a route of abuse that FDA believes is a relatively small aspect of the epidemic.

You may also be interested in...



Keeping Track: Apadaz Approved Without Abuse-Deterrent Label, FDA Denies Translarna Appeal, And Some Priority Reviews

The latest drug development news and highlights from our US FDA Performance Tracker.

KemPharm Seeks FDA Dispute Resolution Over Apadaz's Abuse Deterrence

Sponsor hopes to demonstrate that FDA's process for reviewing extended-release abuse-deterrent opioids may not be appropriate for an immediate-release product. Apadaz would be the first immediate-release opioid with an abuse-deterrent claim if approved.

Purdue's $8.3bn Settlement With DOJ Requires Reconstitution As Public Benefit Company

Purdue pleads guilty to three felony charges over marketing of OxyContin under settlement that requires Purdue to be dissolved and transformed into an entity that provides addiction and overdose medicines. Twenty-five state AGs oppose creation of a PBC, arguing Purdue should be sold to another company.

Topics

Related Companies

UsernamePublicRestriction

Register

ID034708

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel